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ABSTRACT
A LC-HRMS (liquid chromatography coupled with high resolution mass spectrometry) method for the detection and
quantitation of several synthetic cannabinoids (JWH-018, JWH-019, JWH-073, JWH-081, JWH-122 JWH-200, JWH-250, AM-2201,
(±)-CP 47,497, (C8)-CP 47,497, HU-211) and selected metabolites (JWH-018 N-(4-hydroxypentyl) and JWH-073
N-(3-hydroxybutyl)) in whole blood and urine was developed and validated. These methods were applied to postmortem cases
from the Johannesburg Forensic Pathology Services Medicolegal Laboratory (FPS-MLL) to assess the prevalence of these
synthetic cannabinoids amongst the local postmortem population. Urine samples were extracted utilizing a solid phase extraction
(SPE) method, while blood samples were extracted utilizing liquid-liquid extraction (LLE) method. The accuracy of the analytes
ranged from 88–107 % in whole blood (relative standard deviation (RSD) = 7.5–15.0 %), and from 95–109 % in urine (RSD =
4.9–11.9 %). The limits of detection (LOD) and the limits of quantitation (LOQ) for the analytes ranged between 0.675 ng mL–1 and
3.375 ng mL–1 in whole blood, and between 0.225 ng mL–1 to 3.375 ng mL–1 in urine. None of the postmortem cases tested positive for
any of the targeted analytes. The sample population could be extended to living subjects such as those in drug rehabilitation
centres or in hospitals to obtain a more accurate representation of the overall usage in South Africa.
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1. Introduction
Huffman in 1994 designed new compounds with effects com-
parable to natural cannabinoids like tetrahydrocannabinol
(THC). This resulted in the synthesis of JWH-018, which, along
with C8 analogues of the cannabinoid CP 47,497 which are the
most common synthetic additives in a variety of herbal blends
known as ‘Spice’.1,2 ‘Spice’ (and associated names such as K2)
has been sold in numerous countries since 2004 and is marketed
as incense, although it is smoked by users.1 Its popularity can be
attributed to the fact that commonly used drug tests at the time
were unable to detect these drugs in urine and blood as well as
its ease of availability, from head shops (shops selling predomi-
nantly cannabis-smoking accessories) and the internet. Further-
more, ‘Spice’ is sold without age restriction by vendors. These
products are sold for prices between 5 USD and 15 USD per
gram.3,4
There have been numerous case reports which have docu-
mented the psychopathological and neuropsychiatric effects of
certain synthetic cannabinoids.The effects included: blurred
vision, tremors, agitation, anxiety, hallucinations, nausea, vomit-
ing, psychosis, paranoia, tachycardia, hypokalemia, and hyper-
tension.5–8
In recent years the use of these substances has been found in
several countries such as America,9,10 the U.K.,10 Australia,11,12 and
Germany,13,14 but a comprehensive PubMed search revealed no
published research in South Africa.
Methods previously reported included LC-MS/MS,13–16 as well
as matrix-assisted laser desorption ionisation - time of flight
mass spectrometry (MALDI-TOF-MS).17 Newer methods in-
clude UPLC-TOF18 and UPLC-MS/MS.19
A validated method for the analysis of these compounds could
be instrumental in law enforcement’s fight against illegal drugs
in South Africa.
2. Experimental
2.1. Reagents, Standards and Samples
Spice Cannabinoid Mix 1 consisting of JWH-200, JWH-250,
(±)-CP 47,497, (C8)-CP 47,497, and HU-211; Spice Cannabinoid
Mix 2 consisting of JWH-019, JWH-081, JWH-122, and AM-2201;
THC, 11-OH-THC (11-Hydroxy-D9-tetrahydrocannabinol),
JWH-073, JWH-018 N-(4-hydroxypentyl) metabolite, and JWH-
073 N-(3-hydroxybutyl) metabolite solutions were purchased
from Cerilliant, Sigma-Aldrich (Round Rock, United States of
America). JWH-018 and JWH-200 solutions were purchased
from Cayman Chemical (Ann Arbor, United States of America).
1-Naphthalenyl (1-pentyl-1H-indol-3-yl)-methanone-D11
(JWH-018-D11) and (1-Butyl-1H-indol-3-yl)-1-naphthalenyl-
methanone-D9 (JWH-073-D9) solutions were purchased from
Chiron AS (Trondheim, Norway). Analytical grade chemicals
were purchased from a variety of suppliers: Beta glucuronidase/
arylsulphatase ((Roche; Basel, Switzerland)); di-potassium hy-
drogen orthophosphate, sodium carbonate, sodium dihydrogen
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orthophosphate, and sodium hydroxide (Associated Chemical
Enterprises, ACE; Johannesburg, South Africa); HPLC-grade
acetonitrile, methanol (Honeywell Burdick and Jackson;
Muskegon, U.S.A.); HPLC-grade 1-chlorobutane (Minema;
Johannesburg, South Africa); ethanol (Radchem; Johannesburg,
South Africa); dichloromethane, (RCI Labscan; Bangkok, Thai-
land); and 1-chlorobutane, formic acid, and sodium acetate
(Sigma-Aldrich; Round Rock, U.S.A.). Double deionized water
from a Siemens LaboStar evoqua water purifier was used for this
research.
A combined synthetic cannabinoids spiking solution was pre-
pared in methanol containing 1 µg mL–1 of each of the standards
and was stored at –20 °C. Calibration and Quality Control stan-
dards (QCs) were prepared by spiking blank urine and whole
blood from known drug-free volunteers at the following
concentrations; urine calibration standards: 0.0225 ng mL–1,
0.225 ng mL–1, 1.125 ng mL–1, 2.25 ng mL–1, 3.375 ng mL–1,
4.5 ng mL–1, and 6.75 ng mL–1; urine QCs: High (4.5 ng mL–1),
Medium (1.125 ng mL–1), and Low (0.1125 ng mL–1); blood cali-
bration standards: 0.0675 ng mL–1, 0.675 ng mL–1, 3.375 ng mL–1,
6.75 ng mL–1, 10.125 ng mL–1, 13.5 ng mL–1, and 20.25 ng mL–1;
blood QCs: High (13.5 ng mL–1), Medium (3.375 ng mL–1), and
Low (0.3375 ng mL–1).
A combined internal standard solution was prepared in meth-
anol containing 1-naphthalenyl (1-pentyl-1H-indol-3-yl)-
methanone-D11 (JWH-018-D11) and (1-butyl-1H-indol-3-yl)-1-
naphthalenyl-methanone-D9 (JWH-073-D9) at 30 ng mL
–1.
Samples were collected at the FPS-MLL (Johannesburg, South
Africa) between July 2014 and December 2014. Samples were
obtained during routine medico-legal autopsies, where dissec-
tion and assessment of the body would be conducted for the
purposes of establishing with greater certainty the cause and
circumstance of death as per the South African Inquests Act 58 of
1959, Section 2.20
The population comprised all cases of unnatural deaths fulfill-
ing the study’s acceptance criteria received at the FPS-MLL
Johannesburg, which services the Johannesburg metropolitan
area, over the 5-month period.
Urine (approximately 5–10 mL) (n = 85) was obtained, where
available by puncturing the bladder using a syringe and needle.
Blood (approximately 5 mL) (n = 126) was obtained using a
syringe and needle from an incision made at the inner femoral
region, and if this was unsuccessful, it was obtained from the
upper subclavian region.
2.2. Sample Preparation
Samples were analysed at the Laboratory of the National
Horseracing Authority of Southern Africa situated at the
Turffontein Racecourse.
The extraction procedure (adapted from that used routinely at
the Laboratory of the National Horseracing Authority of South-
ern Africa) required 3 mL of urine sample, calibration standard
(urine calibration standards: 0.0225 ng mL–1, 0.225 ng mL–1,
1.125 ng/mL, 2.25 ng mL–1, 3.375 ng mL–1, 4.5 ng mL–1, and
6.75 ng mL–1; blood calibration standards: 0.0675 ng mL–1,
0.675 ng mL–1, 3.375 ng mL–1, 6.75 ng mL–1, 10.125 ng mL–1,
13.5 ng mL–1, and 20.25 ng mL–1) and QC (urine QCs: High
(4.5 ng mL–1), Medium (1.125 ng mL–1), and Low (0.1125 ng mL–1);
blood QCs: High (13.5 ng mL–1), Medium (3.375 ng mL–1), and
Low (0.3375 ng mL–1)) to be transferred into separate 50 mL glass
tubes. Sodium acetate buffer (3 mL of 2 M solution at pH 5.5) and
20 µL of beta glucuronidase/arylsulphatase solution was added
to each sample and left to hydrolyse overnight in a water bath at
37 °C. This was followed by the addition of 160 µL of 5 M aqueous
sodium hydroxide and 3 mL of 0.25 M phosphate buffer (pH 8).
Samples were vortexed and left to stand for 30 min to reach room
temperature, after which 100 µL of the combined internal stan-
dard solution was added and the samples were centrifuged for
20 min at approximately 3000 g. Samples were applied to C18 SPE
cartridges conditioned with 2 mL MeOH followed by 2 mL
double deionized water. The columns were eluted with 8 mL
dichloromethane:ethanol (96:4), and the eluant subsequently
dried under nitrogen gas at 40 °C (5–10 psi), followed by reconsti-
tution in 100 µL methanol.
The method for the analysis of whole blood was based on a
previously developed LLE method.21 Extraction was conducted
by adding 1 mL of sample, 2 mL of sodium carbonate buffer
(pH 9.0), 50 µL internal standard solution (30 ng mL–1), and 10 mL
of 1-chlorobutane: isopropanol (90:10) to a tube. The contents of
the tube was mixed, and centrifuged for 15 min at 3000 g. The
tube was frozen in a dry ice bath and the organic layer trans-
ferred to a new glass tube. The organic layer was evaporated
to dryness under nitrogen gas and reconstituted in 100 µL
methanol.
2.3. Instrumentation and Method
Compounds were separated using an Agilent 1260 Infinity
HPLC system with a Waters XSelect CSH C18, 150 × 2 mm (5 µm)
column (purchased from Waters; Milford, U.S.A.). Mobile phase
consisted of a gradient of water to acetonitrile, both containing 5
mM ammonium acetate buffer and 0.1 % formic acid. The linear
gradient at 0.3 mL min–1 started at 2 min from 2 % to 98 %
acetonitrile at 20 min, held at 98 % until 26 min, followed by a re-
turn to the initial conditions at 28 min. The detector was a
Thermo Fisher Q Exactive Orbitrap High Resolution Mass Spec-
trometer controlled by XCalibur software set at a scan range of
110–700 m/z, resolution of 70 000, AGC target balanced, and a
maximum injection time of 500 ms. A heated electrospray
(HESI-II) ion source was employed using scan to scan positive to
negative ion switching.
2.4. Validation
This method was evaluated in urine and whole blood for the
drugs and metabolites listed in Table 1. Deuterated internal
standards were used to compensate for the loss of analyte
during sample preparation. The validation was performed in
accordance with the guidelines prescribed by SANAS TG 41-01.22
Analytical parameters investigated included selectivity, linear-
ity, limit of detection (LOD), limit of quantitation (LOQ), accu-
racy, precision, recovery, matrix effects, and stability. Seven
calibration standards (two replicates per batch) (urine range:
0.0225–6.75 ng mL–1; blood range: 0.0675–20.25 ng mL–1) were
prepared (in pooled negative urine and whole blood from
volunteers) and analysed on four different days for urine and
three different days for whole blood. Three QCs (three repli-
cates) were included in each batch.
To assess the selectivity of the method the following criteria
were used to process the data: retention time variance £0.3 min
and accurate mass deviation £5 ppm was used to check for
co-eluting or closely eluting compounds within the same accu-
rate mass range.
Blank samples from five individual non-drug users were
analysed with the first batch to check for co-eluting matrix peaks
that could give rise to false positive results.
Linearity was assessed using calibration standards over
the range: 0.0225 ng mL–1 to 6.75 ng mL–1 for urine, and
0.0675 ng mL–1 to 20.25 ng mL–1 for whole blood.
The criteria (based on those used by the Laboratory of the
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National Horseracing Authority of Southern Africa for sub-
stances below 50 ppb) for acceptance for linearity were an
R2 value ³0.970 and a percentage difference of £25 % for calibra-
tion standards and QCs. In addition, no more than two points
were excluded from each set of standards. Failure to meet these
criteria resulted in the validation being rejected for the specific
compound.
The LOD was determined as the lowest calibration standard
which exhibited an S/N ratio ³3, while the LOQ was determined
to be the lowest calibration standard which exhibited an S/N
ratio ³10.
Accuracy and precision were calculated using the three
replicate results for the High QC on four days for urine and three
days for whole blood. Accuracy was represented as the differ-
ence of the QC High and the theoretical value, and precision as
the standard deviation (SD) and coefficient of variance (CV) of
the replicates. Acceptance criteria were values within £25 % of
the theoretical values, % RSD values £15 %, and CV £10.
The matrix effect was not fully investigated in this study but
urine and whole blood samples were taken from five drug-free
volunteers as blank samples. All calibration standards and QCs
were prepared in pooled urine or whole blood, respectively, to
eliminate any matrix effects.
In this study long-term stability of urine and blood was
assessed by storing spiked QCs for 3 months at 4 °C and at –20 °C,
respectively. In addition freeze–thaw stability of the samples
was also assessed (i.e. after being frozen for 3 months the
samples were thawed and frozen three times on three consecu-
tive days, then analysed). Only QC High results (4.5 ng mL–1 in
urine, and 13.5 ng mL–1 in blood) were used to assess stability.
3. Results and Discussion
3.1. Validation
No interfering compounds were found in the blank blood or
urine samples. All the extracted ion peaks fell within the reten-
tion time (0.3 min) and accurate mass (5 ppm) limits.
All of the studied compounds except (±)-CP 47,497 and
(C8)-CP 47,497, showed excellent linearity (R2 ³ 0.970) and met
the criteria for validation as can be seen in Table 1. The results
suggest that the storage conditions of the spiking solution was
not ideal for compounds (±)-CP 47,497 and (C8)-CP 47,497, as all
the other compounds showed good linearity, where the two
mentioned compounds resulted in good linearity only on the
first day and very poor linearity on subsequent days. In this
instance, Ammann et al.21 (who analysed whole blood) also
reported several difficulties with these two compounds as well
as citing possible matrix effects. These two compounds require
negative ionization mode to be detected with LC-MS and
showed a lower response possibly indicating a lower ionization
efficiency of the ESI source.21 This implies that detecting these
compounds is more challenging and may require a targeted
method which isn’t ideal for forensic applications where often a
general screening method is required initially. Scheidweiler and
Huestis23 investigated CP 47,497-type compounds in urine by
LC-MS-MS (liquid chromatography coupled with tandem mass
spectrometry), and reported good linearity. In the current study,
good recoveries were initially observed for (±)-CP 47,497 and
(C8)-CP 47,497 in the first batch (102 and 94 %, respectively),
but the concentration declined rapidly in subsequent batches
conducted over time to below detection limits. This indicates
that these compounds might be unstable during freeze/thaw
cycles or that the storage conditions were not optimal (all
batched were spiked from the same initial spiking solution
which was kept frozen and defrosted every week). Scheidweiler
and Huestis23 only studied stability up to 72 hours, and there
does not appear to be any longer term stability studies on these
compounds. It is possible that this analytical method could be
improved for compounds (±)-CP 47,497 and (C8)-CP 47,497, by
preparing fresh spiking solution with each batch, as well as
including an additional specific internal standard such as
(±)-CP 47,497-d11. This may have implications for forensics
application as these compounds may require a specific targeted
method such as that developed by Dowling and Regan24 (a
LC-MS-MS method specific for CP 47,497 in human urine).
Both the LODs and the LOQs for the analytes ranged between
0.675 ng mL–1 and 3.375 ng mL–1 in whole blood, and between
0.225 ng mL–1 to 3.375 ng mL–1 in urine (seen in Table 1). Seven of
the compounds have the same LOD and LOQ values. This is due
to the lower calibration standard not fulfilling the criteria of S/N
ratio ³3, while the calibration standard above that had an S/N
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Table 1 Validation results.
Whole blood Urine
Drugs Ionization Accurate Retention R2 value LOD LOQ Retention R2 value LOD LOQ
mode mass /amu time /min /ng mL–1 /ng mL–1 time /min /ng mL–1 /ng mL–1
JWH-018 Positive 342.18463 19.38 0.997 0.675 0.675 19.47 0.993 1.125 1.125
JWH-019 Positive 356.20023 20.02 0.998 0.675 0.675 20.12 0.993 1.125 1.125
JWH-073 Positive 328.16898 18.61 0.994 0.675 3.375 18.69 0.996 0.225 0.225
JWH-081 Positive 372.19507 19.65 0.995 0.675 0.675 19.75 0.997 0.225 0.225
JWH-122 Positive 356.20023 20.13 0.994 0.675 3.375 20.23 0.994 1.125 2.250
JWH-200 Positive 385.19031 12.65 0.972 0.675 3.375 12.61 0.994 1.125 2.250
JWH-250 Positive 336.19513 18.37 0.997 0.675 0.675 18.45 0.996 1.125 1.125
AM-2201 Positive 360.17520 17.75 0.989 0.675 0.675 17.83 0.992 1.125 2.250
(±)-CP 47,497 Negative 317.24854 19.00 * * * 19.10 * * *
(C8)-CP 47,497 Negative 331.26425 19.89 * * * 19.99 * * *
HU-211 Positive 387.28876 20.25 0.996 0.675 3.375 20.33 0.992 1.125 2.250
THC Positive 315.23151 20.86 0.993 3.375 3.375 20.97 0.993 1.125 2.250
11-OH-THC Positive 331.22623 17.52 0.995 3.375 3.375 17.58 0.991 3.375 3.375
JWH-018 N-4OH Positive 358.17938 15.36 0.991 0.675 0.675 15.41 0.993 1.125 2.250
pentyl metabolite
JWH-073 N-3OH Positive 344.16388 15.17 0.994 0.675 0.675 15.24 0.997 1.125 1.125
butyl metabolite
* Indicates results that did not meet the validation criteria.
ratio ³10 fulfilling both the LOD and LOQ criteria. In reality, the
LOD lies somewhere between the lower and higher calibration
standard, however no additional calibration standards were
prepared in that range and the exact LOD is not quantifiable
from this study. In future studies additional calibration stan-
dards could be prepared within this range to determine a more
accurate LOD.
Kacinko et al.16 determined the LODs for JWH-018, JWH-019,
JWH-073, and JWH-250 to be between 0.005 ng mL–1 and
0.020 ng mL–1 in whole blood and the LOQ to be 0.1 ng mL–1
(using UPLC-MS-MS), while Holm et al.25 determined the LOD
for 13 synthetic cannabinoids (four of which were in common
with this project) to be in the 0.1 ng mL–1 to 0.25 ng mL–1 range
also in whole blood (using LC-MS-MS). Shanks et al.18 found the
LOD for their studied synthetic cannabinoids (JWH-018 and
JWH-073) in postmortem whole blood to be 0.01 ng mL–1 with a
linear range of 0.05 ng mL–1 to 50 ng mL–1.
The higher LODs and LOQs obtained for whole blood could
be attributed to the method used that had already been opti-
mized and validated for various other drugs of abuse. If one was
only identifying synthetic cannabinoids the method and its
analytical testing parameters could be optimized to achieve
lower LODs and LOQs. In the postmortem forensic setting the
LODs and LOQs from this study are sufficient as most decedents
associated with substances of abuse have levels of the substance
that is far greater than the LOQs. The lower LODs and LOQs
would be significant when attempting to detect trace amounts. A
study conducted on postmortem cases to investigate synthetic
cannabinoid use as a cause or contributory cause of death
included several cases where the levels of several of the
synthetic cannabinoids were below the LOD of this study and
would thus not be detected, which would be a significant
limitation. Labay et al.26 studied 25 cases, eight of which had a
concentration of various synthetic cannabinoids below the
LODs of this study, although four of them also contained addi-
tional synthetic cannabinoids which would have been detected.
Synthetic cannabinoids were not reported as the cause of death
in any of the case studies. The authors concluded that the role of
synthetic cannabinoids in the cause and manner of death was
still not conclusively defined as many of the cases involved alco-
hol as well as other drugs.
Scheidweiler and Huestis23 validated a similar LC-MS method
for 20 synthetic cannabinoids and 21 metabolites in urine (10 of
which were in common with this project) from 0.1 µg mL–1 to
100 µg mL–1 (100 ng mL–1 to 100000 ng mL–1), which is signifi-
cantly higher than the concentration range in this study.
Wohlfarth et al. 27 validated a method for nine synthetic cannabi-
noids and 20 metabolites (eight of which were in common with
this study) in urine and determined their LODs in the range of
0.5 ng mL–1 to 10 ng mL–1, which is comparable to the LODs de-
termined in this project (0.225 ng mL–1–3.375 ng mL–1).
The highest calibration standard for the blood validation was
20.250 ng mL–1 while the highest calibration standard for the
urine validation in this study was 6.750 ng mL–1, resulting in any
values above this would fall outside the calibration range of this
study. Thus a much larger error would be associated with these
values making the method semi-quantitative.
The accuracy of the analytes ranged from 88–107 % in whole
blood, with RSD values of between 7.5 and 15.0 % in whole blood
(Table 2). These values compare well with those reported by
Kacinko et al.16 (91.8 and 108.2 % for all tested analytes except
JWH-019); Ammann et al.21 who reported all analytes to fall
within the acceptance interval of ±15 % (i.e. 85–115 %); and
Shanks et al.19 (99.1–107.0 % for JWH-018 and 97.7–102.0 % for
JWH-073).
The accuracy of the analytes ranged from 95–109 % in urine,
with RSD values between 4.9 and 11.9 % which are well
within the acceptance criteria (Table 2). Due to the low concen-
tration levels of the Low and Medium QCs (falling mostly out-
side the calibration range), the High QC (4.5 ng mL–1 for urine,
13.5 ng mL–1 for whole blood) values were used for all accuracy
and precision calculations.
Reported accuracies for similar synthetic cannabinoid metabo-
lites in urine by other cohorts were comparable whilst included
in a method which allows for the screening of a large number of
different compounds: De Jager et al.,28 73.5–117.5 %; Jang et al.,29
92–108 %; Scheidweiler and Huestis,23 86.5–118.3 %; Simões
et al.,30 90–115 %.
Many of the analytes were stable over the three months in
glass. JWH-018, JWH-073, JWH-081, JWH-200, and JWH-250 in
whole blood, appeared to be stable in plastic at all the tempera-
tures as well as being freeze–thaw stable. No stability data for
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Table 2 Summary of the accuracy and precision of the high QCs of the synthetic cannabinoids in whole blood (13.5 ng mL–1) and urine (4.5 ng mL–1).
Drugs Whole blood Urine
Mean /ng mL–1 Accuracy % S.D. % RSD CV Mean /ng mL–1 Accuracy % S.D. % RSD CV
JWH-018 13.745 102 1.014 7.485 0.075 4.688 104 0.456 9.519 0.095
JWH-019 13.846 103 1.369 10.020 0.100 4.675 104 0.442 9.248 0.092
JWH-073 13.779 102 1.045 7.726 0.077 4.788 106 0.333 6.883 0.069
JWH-081 14.467 107 1.367 9.621 0.096 4.597 102 0.296 6.304 0.063
JWH-122 13.360 99 1.521 11.389 0.114 4.791 106 0.444 9.156 0.092
JWH-200 12.733 94 1.109 8.663 0.087 4.434 99 0.218 4.909 0.049
JWH-250 12.751 94 1.256 9.971 0.100 4.415 98 0.241 5.478 0.055
AM-2201 11.865 88 1.219 9.851 0.099 4.266 95 0.371 9.175 0.092
(±)-CP 47,497 * * * * * * * * * *
(C8)-CP 47,497 * * * * * * * * * *
HU-211 13.834 102 2.020 14.579 0.146 4.885 109 0.241 5.066 0.051
THC 14.210 105 1.889 13.306 0.133 4.573 102 0.365 7.873 0.079
11-OH-THC 13.682 101 1.645 12.197 0.122 4.430 98 0.434 9.629 0.096
JWH-018 N-4OH 12.830 95 1.052 8.196 0.082 4.610 102 0.408 8.933 0.089
pentyl metabolite
JWH-073 N-3OH 12.745 94 1.473 11.577 0.116 4.327 96 0.488 11.858 0.119
butyl metabolite
* Indicates results that did not meet the validation criteria.
CP 47,497, (C8)-CP 47,497, HU-211, and 11-OH-THC could be
obtained as the concentrations were below the detection limits.
Kacinko et al.16 analysed stability of several synthetic
cannabinoids in whole blood in plastic containers with several
common preservatives and concluded that the collection con-
tainer did not affect stability at room temperature, refrigerated
(approximately 3 °C) and frozen (approximately –10 °C) up to 30
days; however, the stability of the compounds longer than that
was not investigated. Amman et al.21 investigated long-term
stability in predominantly JWH-type synthetic cannabinoids,
but only up to 42 days. They found all their studied compounds
to be stable up to that point.
Storage of urine specimens (for 3 months) in glass at –20 °C was
best for most of the compounds as higher recovery and lower
standard deviations were observed. For the majority of the
analytes, storage in plastic containers resulted in lower recover-
ies and exceptionally high standard deviations. Very high recov-
eries (i.e. > 100 %) in several of the samples could be due to
factors such as matrix enhancement or unstable compounds
in the spiking solution. Initially, the stability samples were
prepared at the same time as the spiking solution. The spiking
solution was stored frozen but was defrosted with each batch to
prepare calibration standards and QC samples. Thus, the stabil-
ity samples might have had a higher concentration of drug than
the QCs and calibration standards. This might suggest a need
to prepare a fresh spiking solution so as to eliminate stability
challenges. Whilst several studies were undertaken on urine,
very few have addressed stability. Three groups did not study
stability at all.28,30,31 Two groups23,27 only investigated stability over
3 days. Only Jang et al.29 investigated stability over 30 days (and
reported good stabilities, 96–106 %, for JWH-018 and JWH-073
metabolites).
3.2. Application to Postmortem Forensic Cases
The postmortem forensic samples included 126 whole blood
and 85 urine samples obtained over a 5-month period, from July
2014 to December 2014. Table 3 provides a summary of the
demographic information of the sample population.
An extensive literature search resulted in only one other study
conducted on postmortem cases, and no studies involving syn-
thetic cannabinoids in a South African setting. Shanks et al.19
analysed 45 postmortem blood cases and found either JWH-018,
JWH-073, or both in 18 of the cases. Ammann et al.21 validated
their method in both antemortem and postmortem blood
samples but did not apply their method to actual samples.
Analysing postmortem specimens provides numerous chal-
lenges since there are many factors that can influence the
concentrations of substances of abuse in a decedent. Among
these are postmortem interval (i.e. the time that has elapsed
since a person has died), the condition of the body, very little
knowledge on in vivo stability of these drugs, as well as postmor-
tem redistribution. In South Africa, bodies can be stored for
several days in suboptimal storage conditions, where these
factors play an even larger role.
4. Conclusion
This study aimed to assess how easily the newer synthetic
cannabinoids could be integrated into existing analytical screen-
ing methods. The method for urine specimens currently used
by the Laboratory of the National Horseracing Authority of
Southern Africa, and a whole blood method identified from
literature were found to be suitable for majority of the analytes.
Both these methods are examples of commonly used methods
with common solvents and techniques, allowing for their
potentially easy implementation into local forensic laboratories.
Overall, the majority of the studied synthetic cannabinoids
exhibited excellent linearity (R2 ³ 0.990), as well as good LODs
and LOQs, i.e. 0.225 ng mL–1 and 3.375 ng mL–1 for urine, and
0.675 ng mL–1 and 3.375 ng mL–1 for whole blood, respectively.
The methods were not successfully validated for (±)-CP 47,497
and (C8)-CP 47,497 as ionization efficiency and stability issues
were encountered. Future work on urine samples could also be
extended to the evaluation of other synthetic cannabinoid
metabolites, as this study focused mainly on the parent compo-
nents and only two metabolites were analysed. Further optimi-
zation of negative mode parameters may also improve the signal
intensity and provide better results.
The use of LLE extraction is ideal for the South African envi-
ronment as it is easy to perform, large numbers can be processed
simultaneously, and it requires minimal equipment and appara-
tus (basic glassware is sufficient).
The validation data indicated that the adaptation of existing
routine screening methods to include several synthetic
cannabinoids was mostly successful. This method provides a
sensitive as well as selective way of screening for JWH-018,
JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-250,
AM-2201, HU-211, THC, 11-OH-THC, JWH-018 N-4OH pentyl
metabolite, and JWH-073 N-3OH butyl metabolite in urine and
whole blood.
From the results obtained the scope of research should be
widened to include groups such as drug rehabilitation centres
and seized drugs to obtain a more accurate representation of the
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Table 3 Postmortem cases summary – Demographic information.
Category Sub-category Urine Blood
% distribution % distribution
/n = 85 /n = 126
Age group 15–24 15 15









Sex Male 92 86
Female 8 14
Circumstance Assault 2 2











GSW = Gunshot wound; MBA = Motorbike accident; MVA = Motorist vehicle
accident; PVA = Pedestrian vehicle accident; others include burns electrocution,
and gassing.
extent to which these drugs are being used in South Africa. If
further research amongst these groups were to yield negative
results, it would provide evidence of low prevalence of these
synthetic cannabinoids in South Africa. If, however, positive
results were found, the South African Police Services Forensics
Science Laboratories would need to consider adding a screening
test like the one presented in this study to their testing protocols.
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